Patents Examined by Bridget E. Bunner
  • Anti-Jagged1 antigen binding proteins
    Patent number: 11028180
    Abstract: Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: June 8, 2021
    Assignee: AMGEN INC.
    Inventors: Brian D. Bennett, Chadwick T. King, Jonathan Phillips
  • Notch inhibition in the treatment and prevention of nonalcoholic fatty liver disease
    Patent number: 10988530
    Abstract: The present invention is directed to methods of treating or preventing nonalcoholic fatty liver disease by administering agents that inhibit the NOTCH signaling pathway. Antibodies that inhibit the binding of Delta like 4 ligand (Dll4) to NOTCH receptors may be used for this purpose.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: April 27, 2021
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Masanori Aikawa, Daiju Fukuda, Tetsuro Miyazaki, Elena Aikawa
  • Antibody targeting interleukin 17A and preparation method and application thereof
    Patent number: 10981983
    Abstract: The present invention provides an antibody targeted to interleukin 17A (IL-17A), preparation method and the use thereof. In particular, the invention provides a novel anti-IL-17A monoclonal antibody. The antibody of the present invention is capable of binding IL-17A antigen with high specificity, has high affinity and low immunogenicity, and is used for preparing a medicament for preventing or treating an IL-17A-related disease such as various inflammatory or autoimmune diseases.
    Type: Grant
    Filed: January 19, 2018
    Date of Patent: April 20, 2021
    Assignee: Huabo Biopharm (Shanghai) Co., Ltd.
    Inventors: Xiangyang Zhu, Mingqing Cai, Haijia Yu, Huifeng Jia, Ling Yu
  • Anti-TLR4 antibodies and uses thereof
    Patent number: 10982004
    Abstract: Disclosed are antibodies that specifically bind Toll-like Receptor 4 (TLR-4), and to methods of using the anti-TLR4 antibodies as therapeutics and diagnostic agents.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: April 20, 2021
    Assignee: NovImmune SA
    Inventors: Francois Rousseau, Jeremy Loyau, Nicolas Fischer, Greg Elson, Marie Kosco-Vilbois
  • Methods for reducing severity of pulmonary fibrosis
    Patent number: 10973882
    Abstract: The described invention provides a method of treating a lung injury at risk of progressing to a fibrotic lung disease in a subject in need thereof comprising administering to the subject a composition comprising a therapeutic amount of IL-6 polypeptide, hyaluronan (HA), mimetics thereof, pharmaceutically acceptable salts thereof, or combinations thereof, wherein the therapeutic amount is effective to increase renewal of alveolar epithelial cell 2 (AEC2) stem cells, to repair the injury, to reduce lung fibrosis, or a combination thereof.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: April 13, 2021
    Assignee: Cedars-Sinai Medical Center
    Inventors: Carol Jiurong Liang, Dianhua Jiang, Paul W. Noble
  • BTLA fusion protein agonists and uses thereof
    Patent number: 10961297
    Abstract: The present invention is based on the seminal discovery that BTLA agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind BTLA enhancing BTLA signaling. The present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a BTLA agonist fusion protein as described herein.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: March 30, 2021
    Assignees: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, PFIZER INC.
    Inventors: Carl F. Ware, John Sedy, Tigran Aivazian, Brian Miller, Natasha K. Crellin
  • Bispecific EGFR/IGFIR binding molecules
    Patent number: 10954286
    Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 23, 2021
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao Rakestraw, Marco Gottardis, Joan Carboni
  • Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
    Patent number: 10953048
    Abstract: The present disclosure relates to the acceleration of hematopoietic compartment reconstitution in a subject in need of hematopoietic stem cell transplantation by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein in combination with hematopoietic stem cell transplantation and to the enhancement of hematopoietic compartment autoreconstitution in a subject in need thereof by administering a composition having a protein transduction domain-MYC (PTD-MYC) fusion protein.
    Type: Grant
    Filed: January 29, 2019
    Date of Patent: March 23, 2021
    Assignee: TAIGA BIOTECHNOLOGIES, INC.
    Inventors: Brian C. Turner, Yosef Refaeli, Gregory Alan Bird
  • Antibody formulations
    Patent number: 10947307
    Abstract: Formulations comprising an anti-IL-13 antibody are provided, including pharmaceutical formulations and methods of using such formulations.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: March 16, 2021
    Assignee: Genentech, Inc
    Inventors: Ajay Deshmukh, Joumana Zeid, Thomas M. Scherer
  • Composition for treatment of disorders
    Patent number: 10947308
    Abstract: The invention relates to stable and non-aggregating compositions comprising an IL-17A binding molecule, in particular a single domain antibody. Such compositions are useful for topical administration in the treatment of disease, for example skin disease or asthma.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: March 16, 2021
    Assignee: Crescendo Biologics Limited
    Inventors: Karen Bannister, Ulla Lashmar, Daniel Pettit, Thomas Sandal
  • Aluminum based adjuvants for tolerogenic vaccination
    Patent number: 10940200
    Abstract: The present invention provides methods of modulating an immunological disorder or an immune response. The methods include administering to a subject or a cell an effective amount of an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier. Compositions including an autoimmune antigen and an anti-inflammatory cytokine included in an aluminum-based carrier are also provided.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: March 9, 2021
    Assignee: East Carolina University
    Inventor: Mark D. Mannie
  • Method for in vivo expansion of T regulatory cells
    Patent number: 10934364
    Abstract: Compositions specific for TNF-receptor superfamily member 25 (TNFRSF25, DR3) modulate the immune re-sponse by regulating T regulatory cells.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: March 2, 2021
    Assignee: University of Miami
    Inventors: Eckhard R. Podack, Taylor H. Schreiber, Dietlinde-Maria Wolf
  • Anti-BCMA chimeric antigen receptors
    Patent number: 10934337
    Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.
    Type: Grant
    Filed: March 20, 2020
    Date of Patent: March 2, 2021
    Assignee: Cartesian Therapeutics, Inc.
    Inventors: Yi Zhang, C. Andrew Stewart, Metin Kurtoglu, Murat V. Kalayoglu, Michael S. Singer
  • Vaccines with interleukin-33 as an adjuvant
    Patent number: 10933130
    Abstract: Disclosed herein is a vaccine comprising an antigen and IL-33. Also disclosed herein is a method for increasing an immune response in a subject in need thereof. Further disclosed herein is a method for treating cancer in a subject in need thereof. The methods may comprise administering the vaccine to the subject.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: March 2, 2021
    Assignees: The Trustees of the University of Pennsylvania, Inovio Pharmaceuticals, Inc.
    Inventors: David Weiner, Daniel Villarreal, Matthew Morrow, Jian Yan
  • Serum albumin-binding fibronectin type III domains
    Patent number: 10925932
    Abstract: Fibronectin type III domains (FN3) that specifically bind to serum albumin, related polynucleotides capable of encoding serum albumin-specific FN3 domains, cells expressing the FN3 domains, as well as associated vectors, detectably labeled FN3 domains and FN3 domains fused to a heterologous moiety are useful in extending the half-life of molecules in diagnostic and therapeutic applications.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: February 23, 2021
    Assignee: Janssen Biotech, Inc.
    Inventors: Michael Diem, Steven Jacobs, Karyn O'Neil, Thomas Rutkoski
  • CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease
    Patent number: 10928391
    Abstract: Provided herein are compositions, systems, kits, and methods for detecting autoimmune disease (e.g., multiple sclerosis and juvenile idiopathic arthritis), and risk of autoimmune disease, in a subject based on the levels of CD318.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: February 23, 2021
    Assignees: The Cleveland Clinic Foundation, The Regents of the University of Michigan
    Inventors: Feng Lin, David A. Fox
  • Use of jack bean lectin for increasing the abundance of hematopoietic stem cells and progenitor cells in bone marrow and/or epidermal stem cells in skin in vivo
    Patent number: 10918695
    Abstract: A method of treatment of disease condition resulting from deficiency of hematopoietic stem and progenitor cells and/or epidermal stem cells in skin comprising: administering to the subject suffering from said disease conditions, an effective amount of Jack bean lectin or a pharmaceutically acceptable salt thereof for increasing the abundance of hematopoietic stem cells and progenitor cells in bone marrow and/or epidermal stem cells in skin in vivo. Method of treating said conditions in a subject involves administering a single injection of lectin in a dose range of 0.5-2.0 mg/kg body weight to mouse leading to 2.815 to 3.55 fold increase in the abundance of epidermal stem cells in skin and a dose range of 8.0-10.0 mg/Kg body weight to a mouse leading to 2.36 to 6.67-fold increase in the abundance of hematopoietic stem and progenitor cells in bone marrow.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: February 16, 2021
    Assignee: THE SECRETARY, DEPARTMENT OF ATOMIC ENERGY
    Inventors: Deepak Sharma, Santosh Kumar Sandur, Maikho Thoh, Raghavendra Shridhar Patwardhan, Dharmendra K. Maurya, Rahul Checker, Vikram P. Gota, Jayakumar Sundarraj, Haldhar Dev Sarma, Subrata Chattopadhyay
  • Methods and compositions for treating asthma using anti-IL-13 antibodies
    Patent number: 10919961
    Abstract: The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: February 16, 2021
    Assignee: Abbvie, Inc.
    Inventor: Catherine Tripp
  • Biomarkers for diagnosis and prognosis of corneal ectatic disorders
    Patent number: 10914746
    Abstract: The invention relates to the field of the diagnosis and prognosis methods of molecular pathologies. In particular, the invention relates to methods for determining the diagnosis of an ectatic disease of the cornea in a subject, for determining the risk of developing an ectatic disease of the cornea in a subject, for determining the clinical outcome of a subject suffering from an ectatic disease of the cornea and for selecting a subject to be treated with a therapy for an ectatic disease of the cornea based on the determination of the expression levels of TLR2 and/or TLR4 markers. The invention also relates to the use of the TLR2 and/or TLR4 as diagnosis and prognosis markers for an ectatic disease of the cornea.
    Type: Grant
    Filed: February 16, 2016
    Date of Patent: February 9, 2021
    Assignees: UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, SERVIZO GALEGO DE SAUDE (SERGAS)
    Inventors: María Isabel Lema Gesto, José Antonio Castillo Sánchez, Tomás Sobrino Moreiras, Francisco Campos Perez
  • Use of immunomodulatory kits for immunotherapeutic treatment of patients with myeloid leukemias
    Patent number: 10912820
    Abstract: A method for selecting an immunomodulatory kit, selected for an individual patient, for use in the treatment of patients suffering from myeloid leukemias. Different kits are available for selection and ex vivo testing which are composed of substances that have different immunomodulatory effects on leukemia cells. Each kit particularly contains GM-CSF and one (or two) more substances, selected from PICIBANIL, PGE1, PGE2, CALCIMYCIN and TNF?, as well as pharmaceutically acceptable adjuvants. The clinical aim is to modify, once the individually selected immunomodulatory kits were administered, blast cells in the body of the patient such that they turn into a “vaccine” which is able to activate the immunoreactive cells (of the patient or of the stem cell donor) in the body against blast cells.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: February 9, 2021
    Assignee: Modiblast Pharma GmbH
    Inventor: Helga Schmetzer